Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915Georgina V. Long, Jeffrey S. Weber, Hao Tang et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 11
Association of circulating tumor DNA kinetics with disease recurrence in patients with stage IIIB/C/IV melanoma treated with adjuvant immunotherapy in Checkmate 238.Mahrukh M. Syeda, David Polsky, Kao-Tai Tsai et al.|Journal of Clinical Oncology|2023Cited by 6
Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238Mahrukh M. Syeda, David Polsky, Jennifer Wiggins et al.|Clinical Cancer Research|2024Cited by 0